Premium
HPV vaccination: The most pragmatic cervical cancer primary prevention strategy
Author(s) -
Sankaranarayanan Rengaswamy
Publication year - 2015
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2015.02.014
Subject(s) - cervical cancer , medicine , vaccination , hpv vaccines , hpv infection , cervical screening , immunogenicity , low and middle income countries , gynecology , oncology , immunology , cancer , developing country , antibody , biology , ecology
The evidence that high‐risk HPV infections cause cervical cancers has led to two new approaches for cervical cancer control: vaccination to prevent HPV infections, and HPV screening to detect and treat cervical precancerous lesions. Two vaccines are currently available: quadrivalent vaccine targeting oncogenic HPV types 16, 18, 6, and 11, and bivalent vaccine targeting HPV 16 and 18. Both vaccines have demonstrated remarkable immunogenicity and substantial protection against persistent infection and high‐grade cervical cancer precursors caused by HPV 16 and 18 in HPV‐naïve women, and have the potential to prevent 70% of cervical cancers in adequately vaccinated populations. HPV vaccination is now implemented in national programs in 62 countries, including some low‐ and middle‐income countries. The early findings from routine national programs in high‐income countries are instructive to encourage low‐ and middle‐income countries with a high risk of cervical cancer to roll out HPV vaccination programs and to introduce resource‐appropriate cervical screening programs.